Select from the featured topics below:

Targeting Immune Dysregulation: Evolution of IRT

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
Ottawa Hospital Research Institute

Biography   Abstract


Peter A. Calabresi, MD
Johns Hopkins University Medical Center

Biography   Abstract


Rebecca S. Farber, MD
Columbia University MS Clinical Care and Research Center

Biography   Abstract


Claire S. Riley, MD
Columbia University MS Clinical Care and Research Center

Biography   Abstract


Marijean A. Buhse, PhD, ANP, RN, MSCN
Stony Brook University Medical Center

Biography   Abstract


Carrie L. Sammarco, DrNP, FNP-C, MSCN
NYU Langone Medical Center/Hospital for Joint Diseases

Biography   Abstract


Jonathan E. Howard, MD
NYU Langone Medical Center/ Hospital for Joint Diseases

Biography   Abstract


Updates of Late-Breaking
Data & Abstracts


Advances in the treatment of relapsing multiple sclerosis (RMS) have reshaped the way clinicians and patients approach this disabling chronic disorder, which affects individuals in their most productive working and childbearing years and is a significant cause of disability. Currently, management consists of first-generation disease-modifying therapies (DMTs), and has expanded to include oral agents, longer-acting DMT formulations, as well as selective sphingosine 1-phosphate receptor modulators, and selective immune reconstitution therapy. Thus, for the treating clinicians, this broad and expanding therapeutic repertoire improves individualized management of MS, yet makes choices more complex and challenging.
 
Recent and anticipated advances in the field of immunology and the increasing recognition of inflammation as an important component of neurodegeneration are shaping the conceptualization of disease pathophysiology. Thus, clinicians are encouraged to grasp the potential implications for improved healthcare delivery for their patients.  
 
This CME/CNE program provides clinicians with insights and information on the latest advances in the treatment of MS. For both general neurologists, MS specialists, neuroscience nurses and other healthcare professionals, fundamental recognition of the immunopathology of MS will lead to a better understanding of the disease course and an appreciation of the MS therapeutics that are now, more than ever, tailored to the intricacies of the immune system. 
 
Each presentation on this website is available for credit. You may visit as a guest; however, you must register prior to taking the posttest to obtain credit. Registration will also allow you to keep track of presentations that you have viewed and to reprint certificates for activities that you have completed.